Adverse Event Concerns With Solid Biosciences' Candidate DMD Gene Therapy
Cardiopulmonary Symptoms May Have Triggered Clinical Hold
The US FDA has for the second time placed a clinical hold on Solid Biosciences’ potential gene therapy for Duchenne muscular dystrophy, a move linked to a 70% decline in the company’s share price. The company had reported a serious adverse event in a patient treated with higher doses of the viral vector-delivered gene therapy.
